Critique of survival update analysis from two phase III anastrozole clinical trials

Annals of Surgical Oncology

Volumn 6, Issue 8 SUPPL., 1999, Pages

  Buzdar, Aman U ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; MEGESTROL ACETATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; METASTASIS POTENTIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; NITRILES; SURVIVAL RATE; TRIAZOLES;

EID: 0033372413     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Buzdar AU, Jonat W, Howell A, et al., for the Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-52.
2. Buzdar A, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, for the Arimidex Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997;79:730-9.
3. Jonat W, Howell A, Blomqvist C, et al., for the Arimidex Study Group. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
4. Buzdar A, Jonat W, Howell A, et al., for the Arimidex Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
5. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103-11.
6. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
7. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-60.
8. Smith L, Dombernowsky P, Falkson G, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) [Abstract]. Eur J Cancer 1996; 32(Suppl 2):49.
9. Goss P, Wine E, Tannock I, Schwartz IH, Kremer AB, and study group. Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen [Abstract]. Proc Am Soc Clin Oncol 1997;16:155A.
10. Marty M, Gershanovich M, Campos B, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens [Abstract]. Proc Am Soc Clin Oncol 1997;16:156A.
11. Bergh J, Bonneterre J, Illiger HJ, et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [Abstract]. Proc Am Soc Clin Oncol 1997;16:155A.
12. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the "no change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
13. Robertson JFR, Williams MR, Todd J, Nicholson RI, Morgan DAL, Blarney RW. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989;25:469-75.
14. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of Herceptin® (trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC) [Abstract #23]. Breast Can Res Treat 1998;5:232.